Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Head and Neck Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Breast Neoplasms 2Zollinger-Ellison Syndrome 1Uterine Cervical Dysplasia 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Obesity 1Mouth Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inflammation 1Gastrinoma 1Colorectal Neoplasms 1Chemotherapy Effect 1Burkitt Lymphoma 1

Interventions

Capecitabine 4Temozolomide 3Octreotide 3Streptozocin 2Fluorouracil 2Everolimus 2vatalanib 1romidepsin 1regorafenib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Pantoprazole 1Omeprazole 1Leucovorin 1Irinotecan 1Gefitinib 1Doxorubicin 1Cisplatin 1Bortezomib 1Biological Therapy 1Bevacizumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastrinoma × Omeprazole × Clear all
NCT00001191 2017-07-02

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

National Institutes of Health Clinical Center (CC)

Phase 2 Completed

Zollinger-Ellison Syndrome, Gastrinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡